Holen Sie sich die Stockscreener-App
46.50
0.09%
-0.04
Schlusskurs vom Vortag:
$46.54
Offen:
$46.61
24-Stunden-Volumen:
8.43M
Relative Volume:
1.46
Marktkapitalisierung:
$93.16B
Einnahmen:
$43.93B
Nettoeinkommen (Verlust:
$8.53B
KGV:
12.16
EPS:
3.824
Netto-Cashflow:
$5.74B
1W Leistung:
-1.13%
1M Leistung:
-4.38%
6M Leistung:
-20.32%
1J Leistung:
+7.04%
1-Tages-Spanne:
$46.27
$46.82
1-Wochen-Bereich:
$45.83
$47.41
52-Wochen-Spanne:
$42.84
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
46.50 | 93.16B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-15 | Hochstufung | Berenberg | Hold → Buy |
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-07-24 | Eingeleitet | Citigroup | Neutral |
| 2026-07-06 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
Form 13D/A Opera Limited For: 24 September By Investing.com - Investing.com UK
GSK (NYSE: GSK) board members are buying company stock - Stock Titan
Renalytix rises 7% as UBS holding grows and CEO buys shares - Yahoo Finance UK
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Zacks Investment Research - גלובס
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de
BNTX Stock Price, Quote & News - Syfe
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingGrowth Acceleration Report - careplusvn.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingEarnings Decline Risk - dars.gov.et
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingOne-Time Gain Impact - www.dars.gov.et
Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayProfit Cycle Analysis - careplusvn.com
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayRevenue Breakdown Analysis - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayEarnings Power Value - dars.gov.et
GSK (GSK) Latest: Ends Higher by 2.35% at $52.35 at the Close; Market Levels: $49.73 and $54.97 Define the Nearby Reference Levels at the CloseVolume Weighted Price - careplusvn.com
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus Nephritis - GlobeNewswire Inc.
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK (NYSE: GSK) leaders boost share exposure via dividend reinvestment - stocktitan.net
GSK reports Jemperli rectal cancer trial results - grafa.com
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gsk Plc Adr-Aktie (GSK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
0.40%
3.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):